What Is Marfanoid-Progeroid-Lipodystrophy Syndrome?

Marfanoid-progeroid-lipodystrophy syndrome (MPLS) is an extremely rare genetic condition caused by mutations near the tail end of the FBN1 gene, the same gene responsible for classic Marfan syndrome. What sets it apart is a striking combination of three clinical features that do not typically appear together: some of the tall, flexible skeletal traits of Marfan syndrome, an aged (progeroid) facial appearance present from birth, and a near-total absence of body fat known as lipodystrophy. Fewer than a dozen unrelated patients had been described in the medical literature by the time the condition was formally named in 2016, making it one of the rarest connective tissue disorders known.

How the Condition Came To Be Recognized

The earliest reported patients, described in the 2000s, puzzled clinicians because they did not fit neatly into any established diagnosis. Some were initially thought to have neonatal progeroid syndrome (also called Wiedemann-Rautenstrauch syndrome), a separate condition involving premature aging features at birth. But as these children grew older, skeletal characteristics of Marfan syndrome started to emerge, including tall stature, long limbs and fingers, and in some cases aortic dilation or lens problems in the eyes. A 2010 case report of a 25-year-old woman with generalized lipodystrophy, a progeroid look since birth, and a dilated aortic root was among the first to propose that these patients represented a distinct subgroup of Marfan syndrome rather than a variant of neonatal progeroid syndrome.¹

A similar case of a 16-year-old girl, initially suspected at birth of having Wiedemann-Rautenstrauch syndrome, was re-diagnosed after she developed a marfanoid body shape, severe myopia, and aortic bulb dilation. Her genetic testing confirmed a frameshift mutation near the 3′ end of the FBN1 gene, helping solidify the link between these combined features and that specific genetic region.² By 2016, a review of seven unrelated patients with mutations in exon 64 of FBN1 pulled the clinical picture together and proposed the name “marfanoid-progeroid-lipodystrophy syndrome” as a newly recognized fibrillinopathy.³

What Patients Look Like Clinically

The syndrome’s name captures its three defining features, and each one is present to some degree in every reported case.

The marfanoid component involves partial features of Marfan syndrome. Patients tend to be tall with disproportionately long limbs and slender fingers, and they may have joint hypermobility or scoliosis. But the skeletal involvement is generally described as milder than in classic Marfan syndrome. Eye problems are common, particularly severe myopia and, in some individuals, subluxation (partial dislocation) of the lens. Cardiovascular involvement varies: some patients have dilation of the aortic root, the section of the aorta closest to the heart, while others show little or no vascular enlargement.¹

The progeroid component is apparent from infancy. Affected newborns have a facial appearance that looks prematurely aged, with sparse subcutaneous fat over the face giving the skin a thin, somewhat wrinkled look. Distinct facial features can include prominent eyes, a small jaw, and a triangular face shape. These features are what initially led clinicians to mistake the condition for other progeroid syndromes.⁴

The lipodystrophy is congenital, meaning it is present from birth, and tends to be generalized. Patients have very little body fat across most of the body. This is not the same as being thin from high metabolism or poor nutrition; the fat tissue itself is severely reduced, which has downstream metabolic consequences that set this condition apart from simply being underweight.

A Distinctive Growth Pattern in Childhood

One of the most recognizable features in children with MPLS is a peculiar growth trajectory. Height shoots up more rapidly than expected, but weight gain lags far behind. The result is a child who is tall for their age but very lean, with growth charts showing the two measurements diverging sharply. A review of the earliest reported cases identified this combination as a cardinal feature alongside the lipodystrophy and progeroid appearance: premature birth with accelerated linear growth disproportionate to weight gain.⁵

This pattern can actually serve as an early clinical clue. In a newborn with progeroid features and almost no body fat, the accelerating height growth that shows up in the first months and years of life is unusual enough to narrow the diagnostic possibilities considerably, especially if a Marfanoid body habitus begins to emerge alongside it.

Why One Gene Causes Such Different Problems

The FBN1 gene encodes a large precursor protein called profibrillin-1. Under normal circumstances, an enzyme called furin cleaves this precursor into two products: mature fibrillin-1 and a smaller peptide released from the tail end of the molecule.⁶ Mature fibrillin-1 becomes part of connective tissue microfibrils, the structural scaffolding found in skin, blood vessel walls, the skeleton, and the eye. That is why mutations elsewhere in FBN1 cause classic Marfan syndrome with its well-known cardiovascular, skeletal, and ocular features.

The smaller peptide cleaved from profibrillin-1’s tail end is a hormone called asprosin, discovered in 2016. This is where MPLS gets interesting. Asprosin functions as a fasting-induced hunger hormone: it circulates in the blood, stimulates the liver to release glucose, and crosses into the brain to activate appetite-promoting neurons in the hypothalamus.⁷ In the liver, it does this by binding to a specific receptor and triggering a signaling cascade that releases stored glucose.⁸

The mutations that cause MPLS cluster right at the tail end of FBN1, in exon 64 or at the exon 65 boundary. These mutations are typically frameshifts or splice-site changes that truncate the profibrillin-1 molecule in a way that disrupts asprosin production while leaving most of the mature fibrillin-1 portion partially functional. The result is a two-pronged problem: partial loss of normal fibrillin-1 function produces the mild marfanoid skeletal and cardiovascular features, while the loss of asprosin explains the lipodystrophy and the unusual body composition. Without adequate asprosin to drive appetite and glucose mobilization, patients have dramatically reduced fat stores and a metabolic profile consistent with energy underutilization.⁹

This dual mechanism is what makes MPLS biologically fascinating. Most FBN1 mutations cause Marfan syndrome because they damage the fibrillin-1 structural protein in the middle of the molecule. MPLS mutations occupy a very specific neighborhood at the gene’s far end and take out a hormone that was not even known to exist until recently.

Cardiovascular Monitoring

Because MPLS overlaps with Marfan syndrome, the cardiovascular concerns are real but seem to be variable. Some patients develop dilation of the aortic root, which is the primary cause of serious complications in classic Marfan syndrome. In full-blown Marfan syndrome, aortic dilation and dissection are the leading cause of early death, with the condition affecting roughly 1 in 3,000 people across all ethnic groups.¹⁰ MPLS patients appear to carry some of this risk, but the extent is hard to quantify given how few cases exist. The woman in the 2010 case report had a dilated aortic bulb, as did the teenager reported in 2014. Others have had milder or no vascular findings.

The practical takeaway is that regular cardiac imaging is warranted for anyone diagnosed with MPLS, following protocols similar to those used for Marfan syndrome patients. Even when skeletal features are mild, the shared genetic origin means the aorta cannot be assumed to be safe. Eye examinations for myopia and lens subluxation are similarly recommended on an ongoing basis.

How the Diagnosis Is Made

Diagnosis rests on recognizing the clinical triad of marfanoid features, progeroid appearance, and lipodystrophy, then confirming it with genetic testing of the FBN1 gene. A key diagnostic challenge is that newborns with MPLS often do not yet show the marfanoid features. At birth, the progeroid face and absent body fat dominate the picture, which is why several early cases were misdiagnosed as Wiedemann-Rautenstrauch syndrome or other neonatal progeroid conditions. It is only as the child grows and the tall stature, long limbs, and eye problems appear that the marfanoid component becomes obvious.

Genetic testing looks for mutations near the 3′ end of FBN1, particularly in exon 64 or at the boundary with exon 65. All reported mutations have been frameshift or splice-site changes in this narrow region. A recently described case demonstrated that a splice-site variant at the exon 65 boundary caused skipping of that exon, which escaped the cell’s usual quality-control system for faulty genetic messages and instead produced a truncated protein.¹¹ This kind of molecular detective work matters because standard gene-sequencing panels might flag the mutation as just another FBN1 variant without recognizing the specific consequences for asprosin production.

Clinicians encountering a newborn with progeroid features and severe congenital lipodystrophy should keep MPLS in mind, especially if growth patterns later show the characteristic height-weight divergence. Early genetic testing targeting the distal end of FBN1 can provide a definitive answer before the full clinical picture emerges.

Preclinical Research and Mouse Models

Animal models have been instrumental in understanding how the loss of asprosin drives the metabolic features of MPLS. Researchers created a mouse carrying a small deletion at the exon 65 boundary of the Fbn1 gene, replicating the type of truncating mutation seen in human patients. Mice with one copy of this mutation (mirroring the heterozygous state in humans) showed reduced appetite and less body fat, reproducing the key metabolic phenotype of the syndrome.¹⁰

These mice have proven useful beyond MPLS itself. Because their asprosin levels are chronically low, they provide a clean system for studying what asprosin does in a living organism. The observation that reduced asprosin leads to lower appetite and body fat has pointed researchers toward asprosin as a potential drug target for conditions at the opposite end of the metabolic spectrum: obesity and type 2 diabetes, where too much appetite drive and excessive glucose mobilization are part of the problem.

Asprosin as a Therapeutic Target for Obesity and Diabetes

The discovery of asprosin through the study of MPLS patients is one of those cases where a vanishingly rare disease illuminated something fundamental about human biology. Asprosin had been hiding in plain sight as the tail end of a well-known protein, but nobody realized it was a hormone with its own physiological role until genetic studies of these progeroid-lipodystrophic patients pointed to it.

Research has moved quickly into therapeutic territory. Anti-asprosin monoclonal antibodies have been shown in preclinical work to reduce blood glucose, appetite, and body weight, validating the hormone as a target for metabolic disease.¹² The logic is straightforward: if MPLS patients lack asprosin and are extremely lean with low appetite, then blocking asprosin in people with obesity or diabetes might reproduce some of that effect therapeutically. Early results in animal models have been encouraging, though the work remains preclinical. Current efforts focus on identifying asprosin’s neuronal receptor in the brain, understanding exactly how fat tissue secretes it, and developing antibody-based therapies that could eventually reach clinical trials.

For MPLS patients themselves, this line of research has a different implication. If asprosin’s biology is fully mapped, it might eventually become possible to treat the metabolic symptoms of the syndrome by supplementing the missing hormone, though this remains speculative. For now, management of MPLS is supportive: monitoring cardiac and ocular health, managing the nutritional challenges of severe lipodystrophy, and tracking the distinctive growth pattern through childhood.

How MPLS Differs from Classic Marfan Syndrome

The two conditions share a genetic home in FBN1 but are clinically distinct in ways that matter for patients and families. Classic Marfan syndrome involves mutations scattered throughout the gene that primarily damage fibrillin-1’s structural role in connective tissue. The major concerns are cardiovascular (aortic dilation and dissection), ocular (lens subluxation), and skeletal (tall stature, scoliosis, chest wall deformities). There is no lipodystrophy and no progeroid appearance.

MPLS mutations, by contrast, are confined to a tiny region at the gene’s far end and specifically knock out asprosin production. The structural fibrillin-1 defects are usually milder, producing partial rather than full Marfan features. But the metabolic consequences, which are absent in Marfan syndrome, dominate the clinical picture. A patient with MPLS is likely to look strikingly different from a patient with classic Marfan syndrome: thinner, with an aged facial appearance, and with a growth history that does not follow the usual Marfan pattern.

The inheritance pattern is autosomal dominant for both conditions, meaning a single mutated copy of FBN1 is sufficient to cause disease. However, many MPLS cases have arisen as new (de novo) mutations rather than being inherited from an affected parent, which is consistent with how rare the condition is. The specificity of the mutation location also means that standard Marfan syndrome genetic panels will detect the variant, but the interpretation requires awareness that mutations in the penultimate exon of FBN1 point to MPLS rather than classic Marfan syndrome.

Living with an Ultra-Rare Diagnosis

With fewer than a dozen reported cases worldwide, MPLS sits in a category of genetic conditions so rare that no formal clinical guidelines exist for management. Patients and their families often face a long diagnostic journey, bouncing between specialists before the constellation of features is recognized as a single entity. The fact that the marfanoid features may not appear until later childhood means that infants with MPLS can spend years being investigated for progeroid syndromes or lipodystrophy subtypes before the unifying diagnosis emerges.

Nutritional management is a persistent challenge. The severe lack of body fat means patients have very little energy reserve, and the reduced appetite drive from low asprosin can make it difficult to maintain adequate caloric intake. Pediatric endocrinologists and dietitians familiar with lipodystrophy syndromes are typically the most helpful specialists for this aspect of care, even though MPLS does not fit neatly into the standard lipodystrophy classification frameworks.¹³

Connecting with lipodystrophy patient communities and Marfan syndrome advocacy organizations can provide some practical support, though neither group’s resources are tailored specifically to MPLS. For families navigating this diagnosis, the most valuable resource may simply be the published case reports themselves, which describe the range of features and outcomes seen so far. As more cases are identified through broader use of genetic testing, the clinical picture will sharpen and more organized guidance may follow.